# Voyager Acquisition Corp./Cayman Islands (VACHU) — merger/spac_merger [completed]
Source: SEC API (secapi.ai) · situation sit_328d2fff389b68808ca9 · retrieved 2026-08-11T15:54:01.606Z

## Overview
VERAXA Biotech AG is an emerging leader in designing novel cancer therapies, building a premier engine for the discovery and development of next-generation antibody-based therapeutics, including bispecific ADCs, bispecific T cell engagers, and other innovative formats.

VERAXA Biotech AG shareholders approved a merger with Voyager Acquisition Corp. (NASDAQ: VACH), a healthcare-focused SPAC sponsored by Cantor Fitzgerald & Co., Voyager Acquisition Sponsor Holdco LLC, and Odeon Capital Group LLC, at an Extraordinary General Meeting on February 27, 2026. The merger will be carried out as an absorption merger, with Veraxa Biotech Holding AG acquiring VERAXA and changing its name to Veraxa Biotech AG. The combined company is expected to trade on NASDAQ under the symbol "VRXA" following closing, subject to approval by Voyager shareholders. VERAXA will continue operating under its existing management team led by CEO Christoph Antz.

## Terms
- Counterparty: Voyager Acquisition Corp. · Deal value: $1.35B · Consideration: stock

## Key dates
- Announced 2026-02-03 · Vote 2026-02-27 · Completed 2026-06-10

## Timeline
- 2026-02-03 · 425 (0001829126-26-000901): 425 - Voyager Acquisition Corp./Cayman Islands — *Veraxa Biotech AG is a Swiss public limited company engaged in biological products development.* On February 2, 2026, Voyager Acquisition Corp. and Veraxa Biotech AG amended their Business Combination Agreement to increase the aggregate merger consideration from $1,300,000,000 to $1,350,000,000. In connection with the closing, the Sponsor agreed to forfeit 200,000 Class B Ordinary Shares and 400,000 SPAC Warrants for no consideration, with an equal number of PubCo Ordinary Shares and PubCo Warrants to be issued to Veraxa shareholders as an adjustment to merger consideration. Additionally, Veraxa waived Section 7.3(a)(i) of the original agreement to permit Voyager to seek shareholder approval to amend its charter to remove the net tangible asset requirement of $5,000,001.
  https://www.sec.gov/Archives/edgar/data/2006815/0001829126-26-000901.txt
- 2026-02-27 · 425 (0001829126-26-001749): 425 - Voyager Acquisition Corp./Cayman Islands — *VERAXA Biotech AG is an emerging leader in designing novel cancer therapies, building a premier engine for the discovery and development of next-generation antibody-based therapeutics, including bispecific ADCs, bispecific T cell engagers, and other innovative formats.* VERAXA Biotech AG shareholders approved a merger with Voyager Acquisition Corp. (NASDAQ: VACH), a healthcare-focused SPAC sponsored by Cantor Fitzgerald & Co., Voyager Acquisition Sponsor Holdco LLC, and Odeon Capital Group LLC, at an Extraordinary General Meeting on February 27, 2026. The merger will be carried out as an absorption merger, with Veraxa Biotech Holding AG acquiring VERAXA and changing its name to Veraxa Biotech AG. The combined company is expected to trade on NASDAQ under the symbol "VRXA" following closing, subject to approval by Voyager shareholders. VERAXA will continue operating under its existing management team led by CEO Christoph Antz.
  https://www.sec.gov/Archives/edgar/data/2006815/0001829126-26-001749.txt
- 2026-06-10 · 25-NSE (0001354457-26-000558): 25-NSE
  https://www.sec.gov/Archives/edgar/data/2006815/000135445726000558/xslF25X02/primary_doc.xml

## Citations
- 0001829126-26-000901 — https://www.sec.gov/cgi-bin/browse-edgar?action=getcompany&type=&dateb=&owner=include&count=40&search_text=000182912626000901
- 0001829126-26-001749 — https://www.sec.gov/cgi-bin/browse-edgar?action=getcompany&type=&dateb=&owner=include&count=40&search_text=000182912626001749
- 0001354457-26-000558 — https://www.sec.gov/cgi-bin/browse-edgar?action=getcompany&type=&dateb=&owner=include&count=40&search_text=000135445726000558